MUMBAI, India, Oct. 11 -- Intellectual Property India has published a patent application (202441028697 A) filed by Cancer Institute (WIA), Chennai, Tamil Nadu, on April 8, 2024, for 'an anticancer activity exhibiting pharmaceutical formulation targeted against hipk2 and nlk kinases.'
Inventor(s) include Gopisetty Gopal; and Rangarajan Aathithya.
The application for the patent was published on Oct. 10, under issue no. 41/2025.
According to the abstract released by the Intellectual Property India: "The present invention discloses an anticancer activity exhibiting pharmaceutical formulation comprises of synergistic combinatorial combinations of HIPK2 inhibitor andp38/NLK inhibitor."
Disclaimer: Curated by HT Syndication....